TD Cowen analyst Dan Brennan raised the firm’s price target on Danaher to $305 from $290 and keeps an Outperform rating on the shares. The firm said while forecasts for 2023 and 2024 are coming down, we see an upward bias which combined with a structurally sound bioprocess market the EAS spin and B/S optionality creates a better stock setup.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DHR:
- Danaher price target raised to $280 from $250 at BofA
- Danaher price target raised to $290 from $260 at Barclays
- Danaher Corporation Earnings Update: Did it Beat Estimate Forecasts?
- Beckman Coulter receives FDA clearance for DxC 500 AU Chemistry Analyzer
- Danaher sees Q3 base business core revenue down low-single digits